Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy?

被引：37

作者：

Giordano, TP

Wright, JA

Hasan, MQ

White, AC

Graviss, EA

Visnegarwala, F

机构：

[1] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA

[2] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA

[3] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2003年 / 37卷 / 03期

关键词：

D O I：

10.1086/376638

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

To determine whether CD4 cell count response to virus suppression during highly active antiretroviral therapy differs according to sex or race/ethnicity, we analyzed data in our observational cohort study for patients receiving their first antiretroviral regimen who experienced virus suppression by 6 months of therapy. In both univariate and multivariate analyses, women had greater CD4 cell count increases, compared with men, as did patients receiving a regimen that did not include a protease inhibitor. Race/ethnicity was not a factor.

引用

收藏

页码：433 / 437

页数：5

相关论文

共 24 条

[1] Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease [J].

Anastos, K ;

Barrón, Y ;

Miotti, P ;

Weiser, B ;

Young, M ;

Hessol, N ;

Greenblatt, RM ;

Cohen, M ;

Augenbraun, M ;

Levine, A ;

Muñoz, A .

ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (17) :1973-1980

[2] Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy [J].

Antinori, A ;

Baldini, F ;

Girardi, E ;

Cingolani, A ;

Zaccarelli, M ;

Di Giambenedetto, S ;

Barracchini, A ;

De Longis, P ;

Murri, R ;

Tozzi, V ;

Ammassari, A ;

Rizzo, MG ;

Ippolito, G ;

De Luca, A .

AIDS, 2001, 15 (12) :1579-1581

[3] Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapy [J].

Bennett, KK ;

DeGruttola, VG ;

Marschner, IC ;

Havlir, DV ;

Richman, DD .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 (01) :20-26

[4] Sex differences in nevirapine rash [J].

Bersoff-Matcha, SJ ;

Miller, WC ;

Aberg, JA ;

van der Horst, C ;

Hamrick, HJ ;

Powderly, WG ;

Mundy, LM .

CLINICAL INFECTIOUS DISEASES, 2001, 32 (01) :124-129

[5]

Centers for Disease Control and Prevention, 2001, HIV AIDS SURVEILLANC, V13, P1

[6] Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression [J].

Dronda, F ;

Moreno, S ;

Moreno, A ;

Casado, JL ;

Pérez-Elías, MJ ;

Antela, A .

CLINICAL INFECTIOUS DISEASES, 2002, 35 (08) :1005-1009

[7]

FINKEL D, 2001, 39 ANN M INF DIS SOC

[8] Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy - The Swiss HIV Cohort Study [J].

Friedl, AC ;

Ledergerber, B ;

Flepp, M ;

Hirschel, B ;

Telenti, A ;

Furrer, H ;

Bucher, HC ;

Bernasconi, E ;

Weber, R .

AIDS, 2001, 15 (14) :1793-1800

[9] Does patient sex affect human immunodeficiency virus levels? [J].

Gandhi, M ;

Bacchetti, P ;

Miotti, P ;

Quinn, TC ;

Veronese, F ;

Greenblatt, RM .

CLINICAL INFECTIOUS DISEASES, 2002, 35 (03) :313-322

[10] The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients [J].

Jensen-Fangel, S ;

Pedersen, L ;

Pedersen, C ;

Larsen, CS ;

Tauris, P ;

Moller, A ;

Sorensen, HT ;

Obel, N .

CLINICAL INFECTIOUS DISEASES, 2002, 35 (12) :1541-1548